Keap1 mutations in lung cancer patients

Sasaki,Hidefumi; Suzuki,Ayumi; Shitara,Masayuki; Okuda,Katsuhiro; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/ol.2013.1427

Keap1 mutations in lung cancer patients

Authors:
- Hidefumi Sasaki
- Ayumi Suzuki
- Masayuki Shitara
- Katsuhiro Okuda
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Published online on: June 26, 2013 https://doi.org/10.3892/ol.2013.1427
Pages: 719-721

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kelch‑like ECH‑associated protein 1 (Keap1) inhibits nuclear factor erythroid 2‑related 2 (NEF2L2; also named NRF2)‑induced cytoprotection and has been hypothesized to represent a candidate tumor suppressor. We have previously reported the somatic mutations of the NRF2 gene (NFE2L2), however, the correlation between the Keap1 mutation and the clinicopathological features of lung cancer has not been well investigated. Therefore, in the present study, the Keap1 mutational status in non‑small cell lung cancer (NSCLC) patients was investigated by reverse transcription PCR and direct sequencing. The study included 76 surgically‑removed lung cancer cases from patients of the Nagoya City University Hospital in which the EGFR and NFE2L2 mutation status was already established. Keap1 mutations were identified in 2 (2.6%) adenocarcinoma patients with a history of heavy smoking. These mutations were identified to exist exclusively. The Keap1 mutation was only detected in patients with advanced adenocarcinoma (4.3%) and the completely exclusive status of this mutation and others, including EGFR, Kas, erbB2 and NRF2L2, is likely to improve the selection of personalized therapy for lung cancer.

View Figures

View References

1	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
2	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Eng J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sasaki H, Endo H, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
4	Soda H, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
5	Lipson D, Capelletti M, Yelensky R, et al: Massively parallel sequencing assay identifies novel ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 18:382–384. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yokota K, Sasaki H, Okuda K, et al: KIF5B/RET fusion gene in surgically treated adenocarcinoma of the lung. Oncol Rep. 28:1187–1192. 2012.PubMed/NCBI
7	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
8	Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
10	Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Clu3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
11	Singh A, Misra V, Thimmulappa RK, et al: Dysfunction KEAP1-NRF2 interaction in non-small-cell lung cancer. PloS Med. 3:e4202006. View Article : Google Scholar : PubMed/NCBI
12	Hayes JD and McMahon M: NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
13	Thimmulappa RK, Mai KH, Srisuma S, et al: Identification of Nrf2- regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62:5196–5203. 2002.
14	Takahashi T, Sonobe M, Menju T, et al: Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J Surg Oncol. 101:500–506. 2010.PubMed/NCBI
15	Too NJ, Kim HR, Kim YR, An CH and Lee SH: Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology. 60:943–952. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sasaki H, Hikosaka Y, Kawano O, et al: Evaluation of Kras mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011. View Article : Google Scholar
17	Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 68:1303–1309. 2008. View Article : Google Scholar : PubMed/NCBI
18	Singh A, Boldin-Adamsky S, Thimmukaooa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
19	Cho JM, Manandhar S, Lee HR, Park HM and Kwak MK: Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI
20	Padmanabhan B, Tong KI, Ohta T, et al: Structural basis for detects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 21:689–700. 2006. View Article : Google Scholar : PubMed/NCBI
21	Shibata T, Kokubu A, Gotoh M, et al: Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterokogy. 135:1358–1368. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sasaki H, Nonaka M, Fujii Y, et al: Expression of the prothymosin-a gene as a prognostic factor in lung cancer. Surg Today. 31:936–938. 2001. View Article : Google Scholar : PubMed/NCBI